PAH

Actelion drug fails trial, denting revenue potential
Actelion drug fails trial, denting revenue potential
Yahoo/Reuters
Actelion
clinical trials
Opsumit
PAH
pulmonary arterial hypertension
Flag link:
J&J's $26 Billion Swiss Drugs Experiment
J&J's $26 Billion Swiss Drugs Experiment
Bloomberg
JNJ
Switzerland
Actelion
M&A
PAH
Flag link:
United Therapeutics sees stepped-up competition and says it's 'a good thing'
United Therapeutics sees stepped-up competition and says it's 'a good thing'
Bizjournals.com
United Therapeutics
PAH
pulmonary arterial hypertension
Flag link:
Could an old Roche arthritis med become a pioneering PAH treatment?
Could an old Roche arthritis med become a pioneering PAH treatment?
BioPharma Dive
Roche
PAH
pulmonary arterial hypertension
tocilizumab
Actemra
Flag link:
Actelion sees Uptravi price of $160,000-170,000/patient
Actelion sees Uptravi price of $160,000-170,000/patient
Yahoo/Reuters
Actelion
Uptravi
PAH
pulmonary arterial hypertension
Flag link:
Actelion says selexipag to enter U.S. market in January
Actelion says selexipag to enter U.S. market in January
Yahoo/Reuters
Actelion
selexipag
Uptravi
PAH
pulmonary arterial hypertension
Flag link:
With Opsumit launch rolling, Actelion doesn't 'need' M&A: CEO
With Opsumit launch rolling, Actelion doesn't 'need' M&A: CEO
Fierce Pharma
Actelion
Opsumit
M&A
PAH
pulmonary arterial hypertension
Flag link:
Gilead Sciences Letairis Wins FDA Nod For PAH: Stock To Recover Soon
Gilead Sciences Letairis Wins FDA Nod For PAH: Stock To Recover Soon
Bidness, ETC
PAH
pulmonary arterial hypertension
FDA
Gilead Sciences
Letairis
Flag link:
Bellerophon shares skyrocket on high blood pressure drug study
Bellerophon shares skyrocket on high blood pressure drug study
Marketwatch
Bellerophon
PAH
Inopulse
clinical trials
pulmonary arterial hypertension
Flag link:
Actelion's Opsumit growth heralds smooth switch off aging Tracleer
Actelion's Opsumit growth heralds smooth switch off aging Tracleer
Fierce Pharma
Actelion
Opsumit
Tracleer
PAH
pulmonary arterial hypertension
Flag link:
Actavis seeking FDA Approval to market generic version of Gilead drug
Actavis seeking FDA Approval to market generic version of Gilead drug
Marketwatch
Actavis
FDA
generics
Gilead Sciences
Letairis
PAH
Flag link:
Deep dive into Actelion's Uptravi data calms investors as FDA decision date nears
Deep dive into Actelion's Uptravi data calms investors as FDA decision date nears
Fierce Biotech
Actelion
Uptravi
PAH
pulmonary arterial hypertension
Flag link:
Drug-device biotech SteadyMed swings for a $55M IPO
Drug-device biotech SteadyMed swings for a $55M IPO
Fierce Biotech
devices
SteadyMed
IPOs
biotech
PAH
Flag link:
GSK and Gilead’s combination therapy: positive results in PAH
GSK and Gilead’s combination therapy: positive results in PAH
Pharmaphorum
GSK
Gilead Sciences
PAH
pulmonary arterial hypertension
Letairis
Adcirca
Flag link:
Arena Pharmaceuticals' APD811 Gets Orphan Drug Status
Arena Pharmaceuticals' APD811 Gets Orphan Drug Status
Yahoo/Zacks.com
Arena Pharmaceuticals
APD811
orphan drugs
PAH
pulmonary arterial hypertension
Flag link:
Actelion’s Lung Drug May Face Study Against Gilead Rival
Actelion’s Lung Drug May Face Study Against Gilead Rival
Bloomberg
Actelion
Gilead Sciences
Opsumit
Letairis
PAH
pulmonary arterial hypertension
Flag link:
Actelion gets second boost for Opsumit with EU approval
Actelion gets second boost for Opsumit with EU approval
Fierce Pharma
Actelion
Opsumit
Europe
Tracleer
PAH
pulmonary arterial hypertension
Flag link:
United Therapeutics Shares Gain on FDA Hypertension Approval
United Therapeutics Shares Gain on FDA Hypertension Approval
Bloomberg
FDA
United Therapeutics
PAH
pulmonary arterial hypertension
Flag link:
Did One Of The Top 10 Upside Surprises In The History Of The Biotech Sector Just Happen?
Did One Of The Top 10 Upside Surprises In The History Of The Biotech Sector Just Happen?
Forbes
Remodulin
PAH
pulmonary arterial hypertension
Orenitram
United Therapeutics
Flag link:
United Therapeutics receives subpoena for 3 drugs
United Therapeutics receives subpoena for 3 drugs
Yahoo/AP
United Therapeutics
PAH
Remodulin
Tyvaso
Adcirca
pulmonary arterial hypertension
Flag link:

Pages